Pfizer Inc. (NYSE:PFE) Q3 2023 Results Earnings Conference Call October 31, 2023 10:00 AM ET
Company Participants
Francesca DeMartino - Chief Investor Relations Officer
Albert Bourla - Chairman and Chief Executive Officer
Dave Denton - Chief Financial Officer and Executive Vice President
Mikael Dolsten - Chief Scientific Officer, President, Pfizer Research & Development
Angela Hwang - Chief Commercial Officer, President, Global Biopharmaceuticals Business
Chris Boshoff - Chief Oncology Research and Development Officer, Executive Vice President
Doug Lankler - Vice President, Assistant General Counsel
Aamir Malik - Chief Business Innovation Officer, Executive Vice President
Conference Call Participants
Robyn Karnauskas - Truist Securities
Trung Huynh - UBS
Umer Raffat - Evercore ISI
Terence Flynn - Morgan Stanley
Steve Scala - TD Cowen
Louise Chen - Cantor Fitzgerald
David Risinger - Leerink Partners
Chris Schott - J.P. Morgan
Mohit Bansal - Wells Fargo
Geoff Meacham - Bank of America
Tim Anderson - Wolfe Research
Chris Shibutani - Goldman Sachs
Carter Gould - Barclays Capital
Ivy Wang - Jefferies
Kerry Holford - Berenberg
Andrew Baum - Citigroup
Evan Seigerman - BMO Capital Markets
Operator
Good day, everyone, and welcome to Pfizer's Third Quarter 2023 Earnings Conference Call. Today's call is being recorded.
At this time, I would like to turn the call over to Mr. Francesca DeMartino, Chief Investor Relations Officer and Senior Vice President. Please go ahead, ma'am.
Francesca DeMartino
Good morning. And welcome to Pfizer's earnings call. I'm Francesca DeMartino, Chief Investor Relations Officer. On behalf of the Pfizer team, thank you for joining us. This call is being made available via audio webcast at pfizer.com.
Earlier this morning, we released our results for the third quarter of 2023. Our earnings materials can be accessed on the IR website at investors.pfizer.com.
I'm joined today by Dr. Albert Bourla, our Chairman and CEO; Dave Denton, our CFO; and Dr. Mikael Dolsten, President, Pfizer Research & Development. Joining for the Q&A session, we will also have Angela Hwang, Chief Commercial Officer and President, Global Biopharmaceuticals Business; Aamir Malik, our Chief Business Innovation Officer; Dr. Chris Boshoff, our Chief Oncology Research & Development Officer; and Doug Lankler, our General Counsel.
Before we get started, I wanted to remind you that we will be making forward-looking statements. I encourage you to read the disclaimer on slide 3. Additional information regarding these statements and our non-GAAP financial measures is available on earnings release and in our SEC Forms 10-K and 10-Q under Risk Factors and Forward-Looking Information and factors that may affect future results. Forward-looking statements on the call are subject to substantial risks and uncertainties, speak only as of the call's original date, and we undertake no obligation to update or revise any of these statements.